The immunology of fibrosis: innate and adaptive responses

Trends in Immunology

Volumn 31, Issue 3, 2010, Pages 110-119

  Wick, Georg ^a,b   Backovic, Aleksandar ^a,b   Rabensteiner, Evelyn ^a,b   Plank, Nadine ^a,b   Schwentner, Christian ^b   Sgonc, Roswitha ^a  

^a Division of Experimental Pathophysiology and Immunology   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY; CYTOKINE; GROWTH FACTOR; IMATINIB; PLACEBO; PROTEIN ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1 ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTERIOSCLEROSIS; BREAST FIBROSIS; CLINICAL TRIAL; DRUG MECHANISM; DRUG PROTEIN BINDING; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; HUMAN; INNATE IMMUNITY; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERISILICONE MAMMARY IMPLANT FIBROSIS; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADAPTIVE IMMUNITY; ANIMALS; FIBROBLASTS; FIBROSIS; HUMANS; IMMUNITY, INNATE;

EID: 77949268329     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2009.12.001     Document Type: Review

References (106)

1. Ajmal N., et al. The effectiveness of sodium 2-mercaptoethane sulfonate (mesna) in reducing capsular formation around implants in a rabbit model. Plast. Reconstr. Surg. 112 (2003) 1455-1461
2. Backovic A., et al. Identification and dynamics of proteins adhering to the surface of medical silicones in vivo and in vitro. J. Proteome Res. 6 (2007) 376-381
3. Demedts M., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353 (2005) 2229-2242
4. Wick G., et al. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu. Rev. Immunol. 22 (2004) 361-403
5. Martinon F., et al. The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 27 (2009) 229-265
6. Cassel S.L., et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 9035-9040
7. Gasse P., et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 179 (2009) 903-913
8. Tedgui A., and Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol. Rev. 86 (2006) 515-581
9. Fallowfield J.A., et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J. Immunol. 178 (2007) 5288-5295
10. Gharaee-Kermani M., et al. CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine 24 (2003) 266-276
11. Rao K.N., and Brown M.A. Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann. N .Y. Acad. Sci. 1143 (2008) 83-104
12. Levi-Schaffer F., and Piliponsky A.M. Tryptase, a novel link between allergic inflammation and fibrosis. Trends Immunol. 24 (2003) 158-161
13. Gao B., et al. Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis. Expert. Rev. Gastroenterol. Hepatol. 1 (2007) 173-180
14. Kim J.H., et al. Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma. Am. J. Pathol. 167 (2005) 1231-1241
15. Melhem A., et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol. 45 (2006) 60-71
16. Muhanna N., et al. Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology 48 (2008) 963-977
17. Castagnoli C., et al. Characterization of T-cell subsets infiltrating post-burn hypertrophic scar tissues. Burns 23 (1997) 565-572
18. Gruber R., et al. Determination of γ/δ and other T-lymphocyte subsets in bronchoalveolar lavage fluid and peripheral blood from patients with sarcoidosis and idiopathic fibrosis of the lung. Apmis 104 (1996) 199-205
19. Tulinska J., et al. Immunomodulatory effects of mineral fibres in occupationally exposed workers. Mutat. Res. 553 (2004) 111-124
20. Notas G., et al. NK and NKT cells in liver injury and fibrosis. Clin. Immunol. 130 (2009) 16-26
21. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214 (2008) 199-210
22. Caldas I.R., et al. Human schistosomiasis mansoni: Immune responses during acute and chronic phases of the infection. Acta Trop. 108 (2008) 109-117
23. Zaccone P., et al. Schistosoma mansoni antigens modulate the activity of the innate immune response and prevent onset of type 1 diabetes. Eur. J. Immunol. 33 (2003) 1439-1449
24. Prakobwong S., et al. Time profiles of the expression of metalloproteinases, tissue inhibitors of metalloproteases, cytokines and collagens in hamsters infected with Opisthorchis viverrini with special reference to peribiliary fibrosis and liver injury. Int. J. Parasitol. 39 (2009) 825-835
25. Rottoli P., et al. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5 (2005) 1423-1430
26. Fuschiotti P., et al. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum. 60 (2009) 1119-1128
27. Wangoo A., et al. Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J. Immunol. 166 (2001) 3432-3439
28. Kurasawa K., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis. Rheum. 43 (2000) 2455-2463
29. Ferretti S., et al. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J. Immunol. 170 (2003) 2106-2112
30. Gu Y., et al. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur. J. Immunol. 38 (2008) 1807-1813
31. Roark C.L., et al. gammadelta T cell: an important source of IL-17. Curr. Opin. Immunol. 20 (2008) 353-357
32. Braun R.K., et al. IL-17 producing γδ T cells are required for a controlled inflammatory response after bleomycin-induced lung injury. Inflammation 31 (2008) 167-179
33. Wilson N.J., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8 (2007) 950-957
34. Yang L., et al. IL-21 and TGF-β are required for differentiation of human T(H)17 cells. Nature 454 (2008) 350-355
35. Annunziato F., et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204 (2007) 1849-1861
36. Fehervari Z., and Sakaguchi S. CD4(+) Tregs and immune control. J. Clin. Invest. 114 (2004) 1209-1217
37. Horani A., et al. Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 292 (2007) G628-G638
38. Brouty-Boye D., et al. Chemokines and CD40 expression in human fibroblasts. Eur. J. Immunol. 30 (2000) 914-919
39. Isom C., et al. Breast implant capsules are partially composed of bone marrow-derived cells. Ann. Plast. Surg. 58 (2007) 377-380
40. Pilling D., et al. Inhibition of fibrocyte differentiation by serum amyloid P. J. Immunol. 171 (2003) 5537-5546
41. Brack A.S., et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 317 (2007) 807-810
42. Hinz B. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 127 (2007) 526-537
43. Kaufman J., et al. Expression of CD154 (CD40 ligand) by human lung fibroblasts: Differential regulation by IFN-gamma and IL-13, and implications for fibrosis. J. Immunol. 172 (2004) 1862-1871
44. Denton C.P., and Abraham D.J. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr. Opin. Rheumatol. 13 (2001) 505-511
45. Wick G., et al. Avian models with spontaneous autoimmune diseases. Adv. Immunol. 92 (2006) 71-117
46. Prelog M., et al. Diminished transforming growth factor beta2 production leads to increased expression of a profibrotic procollagen alpha2 type I messenger RNA variant in embryonic fibroblasts of UCD-200 chickens, a model for systemic sclerosis. Arthritis Rheum. 52 (2005) 1804-1811
47. Whitfield M.L., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12319-12324
48. Mori T., et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J. Cell Physiol. 181 (1999) 153-159
49. Leask A., and Abraham D.J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J. Cell Sci. 119 (2006) 4803-4810
50. Shi-Wen X., et al. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev. 19 (2008) 133-144
51. Holmes A., et al. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J. Biol. Chem. 276 (2001) 10594-10601
52. Bonniaud P., et al. Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis-resistant" Balb/c mouse lungs. Am. J. Respir. Cell Mol. Biol. 31 (2004) 510-516
53. Grotendorst G.R., and Duncan M.R. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J. 19 (2005) 729-738
54. Xu S.W., et al. CCN2 is necessary for adhesive responses to transforming growth factor-beta 1 in embryonic fibroblasts. J. Biol. Chem. 281 (2006) 10715-10726
55. Grotendorst G.R., et al. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J. 18 (2004) 469-479
56. Thannickal V.J., et al. Myofibroblast differentiation by transforming growth factor-beta 1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. 278 (2003) 12384-12389
57. Lenga Y., et al. Osteopontin expression is required for myofibroblast differentiation. Circ. Res. 102 (2008) 319-327
58. Matsui Y., et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II - Induced cardiac hypertrophy. Hypertension 43 (2004) 1195-1201
59. Pardo A., et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2 (2005) e251
60. Berman J.S., et al. Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice. Am. J. Physiol. Lung Cell Mol. Physiol. 286 (2004) L1311-L1318
61. Mori R., et al. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J. Exp. Med. 205 (2008) 43-51
62. Jinnin M., et al. Interleukin-13 stimulates the transcription of the human alpha 2(I) collagen gene in human dermal fibroblasts. J. Biol. Chem. 279 (2004) 41783-41791
63. Fichtner-Feigl S., et al. IL-13 signaling through the IL-13 alpha 2 receptor is involved in induction of TGF-beta 1 production and fibrosis. Nat. Med. 12 (2006) 99-106
64. Sticherling M. The role of endothelin in connective tissue diseases. Rheumatology (Oxford) 45 Suppl. 3 (2006) iii8-10
65. Distler J.H.W., et al. The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis. Rheum. 58 (2008) 2228-2235
66. Denton C.P., et al. Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis - A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis. Rheum. 56 (2007) 323-333
67. Blobe G.C., et al. Mechanisms of disease: Role of transforming growth factor beta in human disease. N. Engl. J. Med. 342 (2000) 1350-1358
68. Zhang-Hoover J., and Stein-Streilein J. Tolerogenic APC generate CD8+ T regulatory cells that modulate pulmonary interstitial fibrosis. J Immunol. 172 (2004) 178-185
69. Li G.M., et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J. Gene Med. 8 (2006) 889-900
70. Ikawa Y., et al. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-induced mouse fibrosis. J. Cell. Physiol. 216 (2008) 680-687
71. Akhmetshina A., et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22 (2008) 2214-2222
72. Varga J., and Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat. Rev. Rheumatol. 5 (2009) 200-206
73. Akhmetshina A., et al. Treatment with Imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheumatism 60 (2009) 219-224
74. Helmby H., and Grencis R.K. Interleukin-1 plays a major role in the development of Th2-mediated immunity. Eur. J. Immunol. 34 (2004) 3674-3681
75. Schmitz J., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (2005) 479-490
76. Martinez F.O., et al. Alternative Activation of Macrophages: An Immunologic Functional Perspective. Annu. Rev. Immunol. 27 (2009) 451-483
77. Hansson G.K. Atherosclerosis - An immune disease - The Anitschkov lecture 2007. Atherosclerosis 202 (2009) 2-10
78. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
79. Amberger A., et al. Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress Chaperones 2 (1997) 94-103
80. Millonig G., et al. The vascular-associated lymphoid tissue: a new site of local immunity. Curr. Opin. Lipidol. 12 (2001) 547-553
81. Grenier, S. et al. (2009) Smooth muscle α-actin and calponin expression and, extracellular matrix production of human coronary artery smooth muscle cells in 3D scaffolds. Tissue Eng. Part A. 15, 3001-3011
82. Speer M.Y., et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ. Res. 104 (2009) 733-765
83. Amorino G.P., and Hoover R.L. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am. J. Pathol. 152 (1998) 199-207
84. Mitchell R.N., and Libby P. Vascular remodeling in transplant vasculopathy. Circ. Res. 100 (2007) 967-978
85. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J. Intern. Med. 263 (2008) 517-527
86. Schneider F., et al. Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation 117 (2008) 931-939
87. Sukhova G.K., et al. Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable human atheromatous plaques. Circulation 99 (1999) 2503-2509
88. Gabrielli A., et al. Mechanisms of disease: Scleroderma. N. Engl. J. Med. 360 (2009) 1989-2003
89. Chizzolini C. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Ann. Med. 39 (2007) 42-53
90. Sgonc R., et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J. Clin. Invest. 98 (1996) 785-792
91. Sgonc R., et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 43 (2000) 2550-2562
92. Laplante P., et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: Implications in the pathophysiology of systemic sclerosis. J. Immunol. 174 (2005) 5740-5749
93. Abraham D.J., et al. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr. Rheumatol. Rep. 9 (2007) 136-143
94. Santiago B., et al. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum. 44 (2001) 1667-1676
95. Rajkumar V.S., et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res. Ther. 7 (2005) R1113-R1123
96. Karasek M.A. Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease?. Med. Hypotheses 68 (2007) 650-655
97. Ponticos M., et al. Pivotal role of connective tissue growth factor in lung fibrosis MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 60 (2009) 2142-2155
98. Verrecchia F., et al. Transforming growth factor-beta signaling through the Smad proteins: Role in systemic sclerosis. Autoimmun. Rev. 5 (2006) 563-569
99. Sgonc R., and Wick G. Pro- and anti-fibrotic effects of TGF-β in scleroderma. Rheumatology (Oxford) 47 Suppl 5 (2008) v5-v7
100. Kamel M., et al. The peri-implant breast capsule: An immunophenotypic study of capsules taken at explantation surgery. J. Biomed. Mater. Res. 58 (2001) 88-96
101. Siggelkow W., et al. Histological analysis of silicone breast implant capsules and correlation with capsular contracture. Biomaterials 24 (2003) 1101-1109
102. Wolfram D., et al. Cellular and molecular composition of fibrous capsules formed around silicone breast implants with special focus on local immune reactions. J. Autoimmun. 23 (2004) 81-91
103. Shanklin D.R., and Smalley D.L. Dynamics of wound healing after silicone device implantation. Exp. Mol. Pathol. 67 (1999) 26-39
104. Hu W.J., et al. Molecular basis of biomaterial-mediated foreign body reactions. Blood 98 (2001) 1231-1238
105. Wolfram D., et al. Altered systemic serologic parameters in patients with silicone mammary implants. Immunol. Lett. 118 (2008) 96-100
106. Backovic A., et al. Simultaneous analysis of multiple serum proteins adhering to the surface of medical grade polydimethylsiloxane elastomers. J. Immunol. Methods 328 (2007) 118-127